Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxis Splits Injectable Generics Business Into Separate Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Abraxis CEO says the separation will allow the research business to focus more on personalized medicine.

You may also be interested in...



Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details

Veteran Merck scientist recruited for personalized-medicine push.

Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details

Veteran Merck scientist recruited for personalized-medicine push.

Abraxane vs. Taxotere: Abraxis Prepares To Go Head-To-Head In Phase III Trials

Study comparing Abraxane to Sanofi’s Taxotere for first-line breast cancer will start in second half, along with lung cancer and melanoma studies.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel